연구동향 분석
박사

A study of tyrosine kinase inhibitor as clinical application feasibility in canine intractable tumor diseases = 개의 난치성 종양질환에서 타이로신 키나제 억제제의 임상적 적용 가능성에 대한 연구

최을수 2016년

논문상세정보
인용/피인용
' A study of tyrosine kinase inhibitor as clinical application feasibility in canine intractable tumor diseases = 개의 난치성 종양질환에서 타이로신 키나제 억제제의 임상적 적용 가능성에 대한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • refractory tumor
  • tyrosine kinase inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
23 0

0.0%

' A study of tyrosine kinase inhibitor as clinical application feasibility in canine intractable tumor diseases = 개의 난치성 종양질환에서 타이로신 키나제 억제제의 임상적 적용 가능성에 대한 연구' 의 참고문헌

  • stman, A. 2004. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15(4) : 275-286.
  • ren, A., Merchant, M., Sun, C., Vitolo, M., Sun, Y., Tsokos, M., Illei, P., Ladanyi, M., Passaniti, A. and Mackall, C. 2003. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene. 22(15) : 2334-2342.
  • Yamazaki, K., Sakamoto, M., Ohta, T., Kanai, Y., Ohki, M. and Hirohashi, S. 2003. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 22(6) : 847- 852.
  • Yamamoto, S., Mochizuki, H., Hase, K., Yamamoto, T., Ohkusa, Y., Yokoyama, S., Ushitani, Y. and Tamakuma, S. 1993. Assessment of clinicopathologic features of colorectal mucinous adenocarcinoma. The American journal of surgery. 166(3) : 257-261.
  • Yamamoto, S., Fukushima, R., Hirakawa, A., Abe, M., Kobayashi, M. and Machida, N. 2013. Histopathological and immunohistochemical evaluation of malignant potential in canine aortic body tumours. J. Comp. Pathol. 149(2) : 182-191.
  • Withrow, S. J., Vail, D. M. and Page, R. 2013. Withrow and MacEwen's Small Animal Clinical Oncology. Elsevier Health Sciences : 405-406.
  • Wey, A. C. and Moore, F. M. 2012. Right atrial chromaffin paraganglioma in a dog. Journal of Veterinary Cardiology. 14(3) : 459-464.
  • Veikkola, T., Karkkainen, M., Claesson-Welsh, L. and Alitalo, K. 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60(2) : 203-212.
  • Van Etten, R. A. 1999. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 9(5) : 179-186.
  • Swann, H. M. and Holt, D. E. 2002. Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986–1999) and literature review. J. Am. Anim. Hosp. Assoc. 38(2) : 157-164.
  • Suzuki, S., Dobashi, Y., Hatakeyama, Y., Tajiri, R., Fujimura, T., Heldin, C. H. and Ooi, A. 2010. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 10 : 659- 2407-10-659.
  • Sulzbacher, I., Tr xler, M., Mosberger, I., Lang, S. and Chott, A. 2000. Plateletderived growth factor-AA and-α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Modern Pathology. 13(6) : 632-637.
  • Stock, P., Monga, D., Tan, X., Micsenyi, A., Loizos, N. and Monga, S. P. 2007. Platelet- derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol. Cancer. Ther. 6(7) : 1932-1941.
  • Staser, K., Yang, F. C. and Clapp, D. W. 2012. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu. Rev. Pathol. 7 : 469-495.
  • Staser, K., Yang, F. C. and Clapp, D. W. 2010. Mast cells and the neurofibroma microenvironment. Blood. 116(2) : 157-164.
  • Rivet, J., Mourah, S., Murata, H., Mounier, N., Pisonero, H., Mongiat‐Artus, P., Teillac, P., Calvo, F., Janin, A. and Dosquet, C. 2008. VEGF and VEGFR‐1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer. 112(2) : 433-442.
  • Rini, B. I. and Small, E. J. 2005. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23(5) : 1028-1043.
  • Rajagopalan, V., Jesty, S., Craig, L. and Gompf, R. 2013. Comparison of presumptive echocardiographic and definitive diagnoses of cardiac tumors in dogs. Journal of Veterinary Internal Medicine. 27(5) : 1092-1096.
  • Raica, M., Cimpean, A. M. and Anghel, A. 2007. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma. Neoplasma. 54(4) : 278-284.
  • Petit, A., Castillo, M., Santos, M., Mellado, B., Alcover, J. B. and Mallofr , C. 2004. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am. J. Surg. Pathol. 28(5) : 676-678.
  • Peeters, D., Clercx, C., Thiry, A., Hamaide, A., Snaps, F., Henroteaux, M., Ogilvie, G. K. and Day, M. J. 2001. Resolution of Paraneoplastic Leukocytosis and Hypertrophic Osteopathy after Resection of a Renal Transitional Cell Carcinoma Producing Granulocyte‐Macrophage Colony‐Stimulating Factor in a Young Bull Terrier. Journal of Veterinary Internal Medicine. 15(4) : 407-411.
  • Patnaik, A. K., Hurvitz, A. I., Lieberman, P. H. and Johnson, G. F. 1981. Canine hepatocellular carcinoma. Vet. Pathol. 18(4) : 427-438.
  • Patnaik, A. K., Hurvitz, A. I. and Lieberman, P. H. 1980. Canine hepatic neoplasms: a clinicopathologic study. Vet. Pathol. 17(5) : 553-564.
  • Park, K. S., Lee, J. L., Ahn, H., Koh, J. M., Park, I., Choi, J. S., Kim, Y. R., Park, T. S., Ahn, J. H., Lee, D. H., Kim, T. W. and Lee, J. S. 2009. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn. J. Clin. Oncol. 39(5) : 327-331.
  • Paradis, V., Lagha, N. B., Zeimoura, L., Blanchet, P., Eschwege, P., Ba, N., Benoit, G., Jardin, A. and Bedossa, P. 2000. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Archiv. 436(4) : 351-356.
  • Paoloni, M. C., Penninck, D. G. and Moore, A. S. 2002. Ultrasonographic and clinicopathologic findings in 21 dogs with intestinal adenocarcinoma. Veterinary Radiology & Ultrasound. 43(6) : 562-567.
  • Owen, T. J., Bruyette, D. S. and Layton, C. E. 1996. Chemodectoma in dogs. : 253-265
  • Motzer, R. J. 2003. Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J. Clin. Oncol. 21(7) : 1193-1194.
  • Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H. and Hirashima, T. 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The lancet oncology. 11(2) : 121-128.
  • Meuten DJ. 2002. Tumors of the urinary system. In: Meuten DJ, ed. Tumors in Domestic Animals. 4th ed. Ames: Iowa State Pres :509–546.
  • Maniscalco, L., Iussich, S., Morello, E., Martano, M., Biolatti, B., Riondato, F., Della Salda, L., Romanucci, M., Malatesta, D. and Bongiovanni, L. 2013. PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology. The Veterinary Journal. 195(1) : 41-47.
  • London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., Bergman, P. J., Couto, G. C., Mauldin, G. N. and Michels, G. M. 2009. Multi-center, placebo- controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 15(11) : 3856-3865.
  • London, C. A., Hannah, A. L., Zadovoskaya, R., Chien, M. B., Kollias-Baker, C., Rosenberg, M., Downing, S., Post, G., Boucher, J., Shenoy, N., Mendel, D. B., McMahon, G. and Cherrington, J. M. 2003. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin. Cancer Res. 9(7) : 2755-2768.
  • London, C. A. 2009. Tyrosine kinase inhibitors in veterinary medicine. Topics in companion animal medicine. 24(3) : 106-112.
  • Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., H ussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J. 2008. N. Engl. J. Med. 359 : 378-390.
  • Liptak, J. M., Dernell, W. S., Monnet, E., Powers, B. E., Bachand, A. M., Kenney, J. G. and Withrow, S. J. 2004. Massive hepatocellular carcinoma in dogs: 48 cases (1992- 2002). J. Am. Vet. Med. Assoc. 225(8) : 1225-1230.
  • Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64(2) : 327-336.
  • Lingeman, C. H., Garner, F. M. and Taylor, D. O. 1971. Spontaneous gastric adenocarcinomas of dogs: a review. J. Natl. Cancer Inst. 47(1) : 137-153.
  • Lachowicz, J. L., Post, G. S. and Brodsky, E. 2005. A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats. Journal of veterinary internal medicine. 19(6) : 860-864.
  • Klausner, J. and Caywood, D. 1995. Neoplasms of the urinary tract. Canine and feline hephrology and urology.Philadephia: Lea & Febiger. : 903-907.
  • Kiselyov, A., Balakin, K. V. and Tkachenko, S. E. 2007. VEGF/VEGFR signalling as a target for inhibiting angiogenesis Expert opinion investing drugs 16(1) : 83-107.
  • Katayama, R., Huelsmeyer, M. K., Marr, A. K., Kurzman, I. D., Thamm, D. H. and Vail, D. M. 2004. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother. Pharmacol. 54(1) : 25-33.
  • Jyung, R. W., LeClair, E. E., Bernat, R. A., Kang, T. S., Ung, F., McKenna, M. J. and Tuan, R. S. 2000. Expression of angiogenic growth factors in paragangliomas. Laryngoscope. 110(1) : 161-167.
  • Jung, H. W., Lee, H. C., Kim, J. H., Jang, H. M., Moon, J. H., Sur, J. H., Ha, J. and Jung, D. I. 2014. Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog. J. Vet. Med. Sci. 76(11) : 1545-1548.
  • Jain, R. K. 2014. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 26(5) : 605-622.
  • Jacobowitz, D. 1967. Histochemical studies of the relationship of chromaffin cells and adrenergic nerve fibers to the cardiac ganglia of several species. J. Pharmacol. Exp. Ther. 158(2) : 227-240.
  • Heldin, C., Eriksson, U. and stman, A. 2002. New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 398(2) : 284-290.
  • Heldin, C. 2013. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 11(1) : 97.
  • Head, K., Else, R. and Dubielzig, R. 2002. Tumors of the alimentary tract. Tumors in Domestic Animals, Fourth Edition. : 401-481.
  • Hahn, K., Oglivie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P., Kinet, J. and Palmerini, F. 2008. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine. 22(6) : 1301-1309.
  • Hahn, K. A., Legendre, A. M., Shaw, N. G., Phillips, B., Ogilvie, G. K., Prescott, D. M., Atwater, S. W., Carreras, J. K., Lana, S. E. and Ladue, T. 2010. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am. J. Vet. Res. 71(11) : 1354-1361.
  • Gil da Costa, R. M., Oliveira, J. P., Saraiva, A. L., Seixas, F., Faria, F., Gartner, F., Pires, M. A. and Lopes, C. 2011. Immunohistochemical characterization of 13 canine renal cell carcinomas. Vet. Pathol. 48(2) : 427-432.
  • Ferrara, N. and Kerbel, R. S. 2005. Angiogenesis as a therapeutic target. Nature. 438(7070) : 967-974.
  • Escudier, B., Albiges, L. and Sonpavde, G. 2013. Optimal management of metastatic renal cell carcinoma: current status. Drugs. 73(5) : 427-438.
  • Ellis, L. M. and Hicklin, D. J. 2008. VEGF-targeted therapy: mechanisms of antitumour activity. Nature reviews cancer. 8(8) : 579-591.
  • Edmondson, E. F., Hess, A. M. and Powers, B. E. 2015. Prognostic significance of histologic features in canine renal cell carcinomas: 70 nephrectomies. Vet. Pathol. 52(2) : 260-268.
  • Deim, Z., Szalay, F., Glavits, R., Bauer, A. and Cserni, G. 2007. Carotid body tumor in dog: a case report. Can. Vet. J. 48(8) : 865-867.
  • Cohen, H. T. and McGovern, F. J. 2005. Renal-cell carcinoma. N. Engl. J. Med. 353(23) : 2477-2490.
  • Caywood DD, Osborne CA, Johnston GR. 1980. Neoplasms of the canine and feline urinary tracts. In: Kirk RW, ed. Current Veterinary Therapy VII. Philadelphia: WB Saunders :1203–1208.
  • Cassol, C. A., Winer, D., Liu, W., Guo, M., Ezzat, S. and Asa, S. L. 2014. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Modern Pathology. 27(8) : 1050-1062.
  • Callanan, J., McNeil, P., Anderson, T. and Laird, H. 1991. Metastatic aortic body tumour causing neck pain in a dog. J. Small Anim. Pract. 32(10) : 525-528.
  • Burke, A. 1996. Benign tumors of neural or smooth muscle origin. Atlas of Tumor Pathology, 3rd series, Armed Forces Institute of Pathology, Washington, DC. : 105-110.
  • Brown, P., Rema, A. and Gartner, F. 2003. Immunohistochemical characteristics of canine aortic and carotid body tumours. Journal of Veterinary Medicine Series A. 50(3) : 140-144.
  • Bartlett, D. L., DiBisceglie, A. M. and Dawson, L. A. 2011. Cancer of the liver. In: Cancer: Principles and Practice of Oncology, 9th ed. (De-Vita, V. T., Lawrence, T. S. and Rosenberg, S. A. eds.), Lippincott Williams & Wilkins, Philadelphia : 997–1018.
  • Ayala-Ramirez, M., Chougnet, C. N., Habra, M. A., Palmer, J. L., Leboulleux, S., Cabanillas, M. E., Caramella, C., Anderson, P., Al Ghuzlan, A. and Waguespack, S. G. 2012. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. The Journal of Clinical Endocrinology & Metabolism. 97(11) : 4040-4050.